Acura Pharmaceuticals (ACUR) Announces $5M Milestone Payment
More News related to ACUR
- Acura Pharmaceuticals, Inc. Announces Return of President and CEO From Medical Leave
- Acura Pharmaceuticals, Inc. Reports Second Quarter 2008 Financial Results
- Acura Pharmaceuticals, Inc. Announces Action Regarding Notice of Allowance Received for Second Aversion Technology Patent
- Acura Pharmaceuticals (ACUR) Announces $5M Milestone Payment
- Acura Pharmaceuticals (ACUR) Names Robert B. Jones Chief Operating Officer
Acura Pharmaceuticals, Inc. (Nasdaq: ACUR) announced the receipt of a $5.0 million milestone payment from King Pharmaceuticals, Inc. for successfully achieving the primary end points in Acura's pivotal Phase III study, AP-ADF-105.
Compared to placebo, Acurox Tablets 5/30mg and 7.5/30mg both met the primary pain relief endpoint with p=.0001 and p less than .0001, respectively.
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
